髓过氧化物酶与慢性肾脏病进展、心血管疾病及死亡风险:CRIC研究
该前瞻性队列研究纳入3872例CRIC研究参与者,基线测量髓过氧化物酶(MPO)浓度。调整分析显示,MPO每升高1个标准差(对数转换),CKD进展风险增加10%,心血管疾病风险增加12%,死亡风险增加13%。但调整心脏生物标志物后,MPO与心血管疾病和死亡的关联不再显著。
要点
- MPO每升高1-SD,CKD进展风险增加10%(HR 1.10,95%CI 1.01-1.19)。
- MPO与CVD和死亡的关联在调整心脏生物标志物后不再显著。
- 基线eGFR对MPO与CKD进展的关联存在效应修饰(P交互=0.02)。
核心结论
- 在CRIC研究的CKD患者中,较高的MPO水平与CKD进展风险增加相关,但与CVD和死亡无独立关联。
研究设计与样本
- 前瞻性队列研究,纳入3872例基线测量MPO的CRIC研究参与者,采用Cox比例风险模型分析。
主要发现
- MPO每升高1-SD(对数转换),CKD进展风险增加10%(调整HR 1.10,95%CI 1.01-1.19,P=0.03)。
- MPO每升高1-SD,CVD风险增加12%(调整HR 1.12,95%CI 1.03-1.22,P<0.01)。
- MPO每升高1-SD,死亡风险增加13%(调整HR 1.13,95%CI 1.04-1.22,P<0.01)。
- 调整心脏生物标志物后,MPO与CVD和死亡的关联不再显著。
- 基线eGFR对MPO与CKD进展的关联存在效应修饰(P交互=0.02);分层分析中,eGFR>45mL/min/1.73m2者MPO每升高1-SD的CKD进展风险调整HR为1.23(95%CI 1.03-1.46,P=0.02),eGFR≤45mL/min/1.73m2者为1.10(95%CI 1.02-1.20,P=0.02)。
临床怎么用
- MPO可作为CKD患者肾脏进展风险的潜在生物标志物,尤其在eGFR>45mL/min/1.73m2的患者中关联更强。
- MPO与CVD和死亡的关联可能受心脏生物标志物影响,需进一步研究。
局限性
- 可能存在残余混杂。
- 缺乏MPO的重复测量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Myeloperoxidase (MPO) catalyzes the formation of reactive nitrogen species and levels are elevated in patients with chronic kidney disease (CKD). Although increased oxidative stress and inflammation are associated with progression of CKD and cardiovascular disease (CVD), relationships between MPO concentration, CKD progression, CVD, and death remain unclear. STUDY DESIGN: Prospective cohort. SETTING & PARTICIPANTS: 3,872 participants from the Chronic Renal Insufficiency Cohort (CRIC) who had MPO measured at baseline. EXPOSURE: Baseline MPO concentration. OUTCOMES: CKD progression (kidney transplantation, dialysis initiation, or 50% decline in baseline estimated glomerular filtration rate [eGFR] and eGFR≤15mL/min/1.73m2), CVD (heart failure, myocardial infarction, or stroke), and death. ANALYTICAL APPROACH: Cox proportional hazards models. RESULTS: In adjusted analyses, higher MPO level (per 1-SD increase in log-transformed MPO) was associated with 10% higher risk for CKD progression (adjusted HR, 1.10; 95% CI, 1.01-1.19; P=0.03), 12% higher risk for CVD (adjusted HR, 1.12; 95% CI, 1.03-1.22; P<0.01), and 13% increased risk for death (adjusted HR, 1.13; 95% CI, 1.04-1.22; P<0.01). There was evidence for effect modification of the association of MPO level with CKD progression by baseline eGFR (P interaction=0.02), but not for CVD (P interaction=0.2) or death (P interaction=0.1). In stratified analyses, MPO level (per 1-SD increase in log-transformed MPO) was associated with greater risk for CKD progression among participants with eGFR>45mL/min/1.73m2 (adjusted HR, 1.23; 95% CI, 1.03-1.46; P=0.02) compared with those with eGFR≤45mL/min/1.73m2 (adjusted HR, 1.10; 95% CI, 1.02-1.20; P=0.02). The association of MPO level with CVD and death was no longer significant after adjustment for cardiac biomarkers. LIMITATIONS: Potential residual confounding, lack of repeated measurements of MPO. CONCLUSIONS: Higher MPO level was associated with increased risk for CKD progression, but not with CVD and death in patients with CKD from CRIC. Whether therapies aimed at reducing MPO activity can result in improved clinical outcomes is yet to be determined.
引用
- Correa S, Pena-Esparragoza JK, Scovner KM, et al. Myeloperoxidase and the Risk of CKD Progression, Cardiovascular Disease, and Death in the Chronic Renal Insufficiency Cohort (CRIC) Study. Am J Kidney Dis. 2019. PMID: 31864821. doi:10.1053/j.ajkd.2019.09.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。